MS
Mark Douglas Smith
Director

Mark Douglas Smith insider trades: Jazz Pharmaceuticals (JAZZ) stock buys and sales

Director, Jazz Pharmaceuticals Last trade Jun 15, 2026 33 Form 4 filings
$267K
Sold, last 12 months
1 sale
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2020
3
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Mark reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 15, 2026JAZZ↓ Sell$267K
Jul 2, 2025PHR↓ Sell$203K
Aug 15, 2024TDOC↑ Buy$28K
Jul 18, 2024PHR↓ Sell$175K
Dec 4, 2023JAZZ↓ Sell$50K
Aug 14, 2023JAZZ↓ Sell$171K
Apr 3, 2023PHR↓ Sell$215K
Dec 2, 2022JAZZ↓ Sell$65K
Aug 8, 2022JAZZ↓ Sell$166K
Dec 2, 2021JAZZ↓ Sell$51K
Jan 4, 2021PHR↓ Sell$315K
Aug 10, 2020PHR↓ Sell$182K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other JAZZ insiders

Open-market trades in the last 12 months

About Mark Douglas Smith's insider trades

Mark Douglas Smith is a director at Jazz Pharmaceuticals (JAZZ). Since Aug 10, 2020, Mark has reported 1 open-market purchase worth $28K and 11 sales worth $1.9M on SEC Form 4. In the last 12 months: 1 sale ($267K).

Their filings also include grants and awards (21 filings), option exercises (8 filings), shares withheld for taxes (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every JAZZ insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.